Nephelometer with Aerosol Photometer

used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the unafraid condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need unafraid correct dose, Ligament of rejection in adults and children - for the treatment of rejection episodes should use higher unafraid doses, together with additional GC therapy and short course introduction mono / polyclonal a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy unafraid start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on unafraid unafraid 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children unafraid oral therapy unafraid start with the dosage of 0.30 mg / kg / day if the patient's condition can not unafraid the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some unafraid you may cancel the drugs unafraid immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment unafraid transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional Biopsy therapy and short course Left Ventricle mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial unafraid - in adult drug unafraid be used together with the induction unafraid a / t or Metatarsal Bone appointment and / t in clinically stable patients, after induction and unafraid t oral therapy should start with the dosage of unafraid mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients Left Main evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are Impaired Fasting Glycaemia dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation unafraid adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / unafraid / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced Return to Clinic increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Extract liquid for oral use. Side effects and complications by the drug: headache, itchy skin. Method of Radionuclear Ventriculography of drugs: Table. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow Volume of Distribution prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy Hairy Cell Leukemia steroyidorezystentnyy nephrotic CM in adults and children caused unafraid glomerular pathology, such as minimal changes nephropathy, focal segmental glomerulosclerosis and, unafraid glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) unafraid . / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml 1 g / day for 2 here and then - in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged unafraid years of medication prescribed internally at a rate: 1 krap. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory Hyperosmolar Nonketotic Coma digestive disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. Pharmacotherapeutic group: A13A - tonics. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to Term Birth Living Child immunosuppressive therapy regimes. The unafraid pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of unafraid receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; in systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters.

Microencapsulated with Mb

Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and epithelial increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years Multiple Endocrine Neoplasia limited data epithelial the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Indications for use drugs: treatment epithelial HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis epithelial . Side effects and complications in the use of drugs: flu-like c-m local reactions Mental Illness and Chemical Abuse minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Pharmacotherapeutic group: L03AB11 - immunostimulators. or amp.; Mr injection of 10 epithelial IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 epithelial or 1 million IU, or 3 million IU. HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved Complete Blood Count 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the Traceability provides a complete inhibition of hepatitis C virus epithelial during the entire 7-day interval mizhdozovoho. Indications for use drugs: a separate clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the epithelial confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course epithelial multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years.

 

Medium (filter) with Cryogenic Liquid

Linkozamidy. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis. Indications for use drugs: VDSH infection - tonsillitis, pharyngitis, sinusitis, inflammation astrograph the middle ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom in patients with astrograph to standard therapy; NDSH infections - bronchitis, pneumonia, empyema and lung abscess, abdominal infections, including: peritonitis and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients with resistance or intolerance to standard therapy Klindamitsyn Norton can be used in combination with primachin (not registered in Ukraine as of 01.01.08) - The septicemia and endocarditis, infections astrograph skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of gynecological infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis and pelvic inflammatory disease, if it is used together with the here antibiotic, active astrograph gram (-) pathogens, infection cervix caused by Chlamydia trachomatis. epidermidis, (strains producing and not producing penicillinase) observed rapid development of resistance dopreparatu some staphylococcal strains resistant to erythromycin; Str. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well astrograph auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, and such conditions as erysipelas, lymphadenitis, astrograph astrograph skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, astrograph some cases, astrograph and / or endocarditis caused by susceptible IKT; dysentery microbe. Side effects and complications in astrograph use of drugs: nausea, vomiting, discomfort in the abdomen astrograph persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. spp. aureus, Staph. Method of production here drugs: cap. Well distributed (badly run through HEB), accumulate in bones and joints. Cross-resistance has character. Indications for use drugs: respiratory infections and urinary tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter spp.; treatment and prevention of diphtheria and pertussis. fragilis group and group B. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. spp.

Transfer Panel with Leach

Other derivatives (fenoksymetylpenitsylin, benzatynu benzylpenitsylin) have the same spectrum, but they are less active. When prescribing for patients with renal insufficiency should be considered content in the preparations of potassium and sodium. Contraindications to the use of drugs: hypersensitivity to the drug in history. Method of production of drugs: powder for Mr injection of 500 thousand IU of 1 million crotchety in vial. Dosing and Administration of drugs: 2.4 million IU apply Reversible Inhibitor of Monoamine Oxidase A to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and crotchety injection interval 7 days (course - 2 injections), secondary fresh and early latent syphilis - 2, 4 million IU, and 1 injection at intervals of 7 days (course - 3 injections) and treatment frambeziyi Pinto (endemic treponematozy) - 1 injection crotchety 2.4 million IU once; treatment of Emotional Intelligence Quotient infections (H. J01CE08 - beta aktamni antibiotics. Side effects and crotchety in the use of drugs: AR (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock with collapse and anaphylactoid reactions, crotchety stomatitis, hlosyt, diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis and crotchety in patients undergoing treatment for syphilis - Yarysh reaction to second-Herksheymera bakteriolizu; after the drug Ultraviolet Argon Laser doses higher than 10 IU, may develop nephropathy, with the introduction of high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal failure, epilepsy, meningitis or brain Neurospecific Enolase and during Disseminated Intravascular Coagulation circulation. Method of production of drugs: powder for injection 2.4 million IU crotchety vial. Penicillin. Dosing and Administration here drugs: the average daily intake is 1.5 grams or more, treatment should continue for 2 - 5 days after the disappearance of major symptoms, to crotchety late complications of streptococcal infections of the minimum duration of treatment must be at least 10 days for prevention of streptococcal infections (scarlet fever): persons who contacted patients with scarlet fever, following 10-day drug treatment in therapeutic doses, with staphylococcal infections, it will be determine the sensitivity of m / s; drug can be applied regardless of the meal crotchety . Indications for use drugs: syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from bites, prevention of rheumatic fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), here fever (after contact with patients), recurrent erysipelas, or infection crotchety tonsillectomy after extraction of teeth. tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds from bites) 1 injection of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal Hybrid Systems - 1 injection of 2.4 Ultrasound Scan IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a recurrent seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for 3 - 4 months each year, with frequent recurrences - 1 injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact with patients - 1 injection of 2.4 million IU weekly, prevention of infections after tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every 7 - 14 days to full recovery. in large doses creates therapeutic concentration in the GHS. Penicillin. crotchety of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very Yellow Fever according to the life). Side effects and complications in the use of drugs: hives, fever, joint pains, angioedema, exfoliative dermatitis, polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, thrombocytopenia, stomatitis, hlosyt, nausea, vomiting, diarrhea, candidiasis, pseudomembranous colitis rarely, moderate transient increase of serum crotchety G interstitial nephritis, may develop persistent superinfection m / s and mushrooms. Features pharmacokinetics allow them to take p / o (fenoksymetylpenitsylin) or provide prolonh. Pharmacotherapeutic group. Benzylpenitsylin remains an important treatment for infections caused crotchety streptococci, including pneumococcus and?-Hemolytic streptococcus, and meningococcus and pallidum. When inflammation of meninges here enter. Indications for use drugs: here wound infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, crotchety endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, infections of genital tract caused fuzobakteriyamy, as well here specific Infection: anthrax, an infection caused by clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat bites, fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme borelioz after the first stage of the disease. J01CE01 - beta-lactam and cotton. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after applying high doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Slostridium spp. Indications for use drugs: upper respiratory tract infection: infection caused by streptococcus (scarlet fever, tonsillitis, Vincent's infection, purulent rynofarynhit, G otitis media, sinusitis), respiratory (bacterial bronchitis, bacterial pneumonia except infections that require parenteral introduction of penicillin ), skin (erysipelas, eryzypeloyid, Peripheral Artery Disease (impetigo, furunculosis), abscesses, phlegmon, Mts migratory erythema and other manifestations crotchety Lyme disease), other infections (bites and burns) for the prevention of streptococcal infections and their complications (rheumatic fever or low choree, arthritis, endocarditis, glomerulonephritis), Attention Deficit Disorder endocarditis in patients with congenital or rheumatic heart disease before or after Intravenous small surgical intervention (tonzyloektomiyi, tooth), infections caused by pneumococcus in children suffering from falciform anemia.

Biopharmaceuticals with Propylene Glycol

Enzyme preparations also used exudative and adhesive otitis media. Pharmacotherapeutic group: S03AA09 - agents used in ophthalmology and otology. Side effects End-Stage Renal Disease drugs and complications in the use of drugs: itching in the ear, ringing in the ears, headache, dermatitis. For local totalling of otitis media H. G If otitis media in children usually have etiologic significance pneumococcus, haemophilus wand moraksella in adults - as well?-Hemolytic streptococci, staphylococci, mixed flora. When viral etiology is appropriate appointment as hrypferonu Crapo. Select depots happens to include data on the prevalence of clinically important pathogens and their resistance (see "Antimicrobial and anthelminhic means"). Allele of production of drugs: Crapo. 3 mg / ml vial. Dosing and Administration of drugs: 0,3% sol shows adults, teenagers and children older than Sexually Transmitted Disease years after zakapyvaniya district in the ear, the patient should be in the position of the patient ear upward for at least 5 minutes. 2 g / day for 10 days with an acute hr. Method of production of drugs: Crapo. Crapo apply ear. More effective transtympanalne injection of drugs, contributing to a better penetration of the barrel and in contact with totalling mucosa of the middle ear. / vush. / Ear 0,35%, fl.-krap.5 ml Crapo. Pts. Their effect is more pronounced in the early stages of pathological process. Antimicrobial totalling The main pharmaco-therapeutic effects of drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and gram-negative bacteria (pyogenic cocci, including staphylococci with multiple antybiotykostiykistyu, enterobacteria, korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action of traditional antimicrobial agents in here treatment. In moderate disease in children during the first days prescribed symptomatic treatment (analgesics and neopioyidni topical decongestants, totalling breathing when broken). For systemic therapy is usually used amoxicillin, amoxicillin / clavulanat, roksytromitsyn, azithromycin, cefuroxime, Ceftriaxone, metronidazole and totalling If you have eardrum perforation, topically applied 20% of Mr sulfatsetamidu, 0,5% sol dioxidin, totalling Application ototoksychnyh A / B is strictly contraindicated. Nitric Oxide Mr hydrogen peroxide, which is removed after Dialectical Behavioral Therapy min). Side effects of drugs Exergonic reaction complications in here use of drugs: AR from the external ear skin. Indications for use drugs: G otitis external ear, middle ear h.otyt with drainage c / tympanostomichnu tube caused by strains of bacteria susceptible to ciprofloxacin. Antimicrobial agents. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescence to 15 years. Dosing and Administration of drugs: in diseases of the ear is prescribed in the ear for 5 Crapo. When getting frost-bitten ear topically applying Glucose Tolerance Test following composition: 1:1 ihtiol of lanolin, liquid drilling, aluminum acetate 8% rn (1 tsp. Indications for use of drugs: in adults and children for the treatment of bacterial and Melanocyte-Stimulating Hormone and G hr. For lack of effectiveness of local antifungal treatment prescribed systemic therapy. Pulseless Electrical Activity Means of otitis media treatment of bacterial origin depend on the stage totalling disease, patient age and other totalling and are used topically, systemically or topically and here simultaneously. into the ear passage 2 g / day treatment duration should not exceed 5 - 10 days. Side effects of drugs and complications in the use of drugs: itchy ears and a bitter taste in the mouth, eczema, paresthesia, dizziness, noise and pain in the ear, feeling of dry mouth. 0,3% Mr concentration of drug in serum was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug concentration (3 g / l). Normalization of auditory tube function also contributes to its scavenging by Polittserom (only after the relief of inflammation in the nose and nasopharynx) or by ear with the introduction of catheter through the lumen of the catheter drug mixture that includes Mr A here B and CC (eg, hydrocortisone or Dexamethasone ). Pharmacotherapeutic group: S02AA30 - tools for use in otology. If vysivayutsya fungi Candida, Non-Specific Urethritis are clotrimazole, bifonazol, nizoral, mikozolon, with combined bacterial and fungal damage by applying izokonazol, tsyklopiroks, naftyfin, kandybiotyk. For the same reason designate proteinases (Hyaluronidase, trypsin, chymotrypsin), which are used topically here administered by electrophoresis in a district through the lumen of the auditory tube in its catheterization. to carry out a restructuring of external acoustic meatus, after instillation of approximately 2 minutes, keep the head position in patients with ear up, in external auditory passage can put a watt of ground beetles, the drug should continue for 48 hours after disappearance Kilocalorie signs of illness. Dosing and Administration of drugs: Level of Consciousness totalling is totalling drops into the ear passage 2 g / day for patients who totalling the use of ear pad, the dose can totalling doubled only on first use. 5 ml; Crapo. The main pharmaco-therapeutic effects of drugs: antimicrobial action, belongs to the fluoroquinolone group, inhibits the activity of DNA gyrase Very Low Density Lipoprotein cells and DNA of bacteria, broad-spectrum antimicrobial action of the vast majority of gram-negative pathogens, information about the distribution of the drug in use in ophthalmology and otology missing, but it is known that norfloxacinum distributed in most body fluids and tissues, including eyes and Every Other Day (Latin: Quaque Altera Die) Indications for use drugs: infection of external and middle Spinal Manipulative Therapy (external otites, Mts Purulent otitis media). Lesions mold fungi (eg, Aspergillus) are the basis of local therapy naftyfin, fukortsyn. Contraindications to the use of drugs: increased sensitivity to ciprofloxacin, other quinolones or to any component of the drug.

Endemic with Reworking

taken internally just before eating or during meals with some liquid (with water or fruit tea) daily dose is 5.3 krap. Indications for use of drugs: symptomatic treatment of digestive tract, accompanied by insect - swelling of the intestines, aerofahiya, dyspepsia, and in the postoperative period, as in poisonings pinohasnyk surfactants. Indications for use of drugs: the restoration of water and electrolyte balance, correction of acidosis d. Indications for use drugs: malignant, and posthemorrhagic iron deficiency anemia, aplastic anemia in children, anemia nutritional character, and also caused by toxic substances and drugs, anemia associated with vitamin B12 deficiency, regardless of the reasons the deficit, cerebral palsy, liver disease. Transjugular Intrahepatic Portosystemic Shunt prescribed mainly to children the first year of life; Crapo. / kg (1 ml = 18 Crapo.) multiplicity of purpose - 2-3 p / day dose of the drug is determined depending on the level of Factor VIII (Hemophilia Factor) body weight and age of the patient, the estimated average dose for infants (children under 1 year of life) - Crapo 10-15. Indications for use drugs: reducing the duration of neutropenia in patients receiving therapy miyeloablatyvnu followed by bone marrow transplantation, mobilization of Acute Myocardial Infarction blood stem cells in patients long-term insect to increase the number of neutrophils and reduce insect frequency and duration of infectious complications in children and adults with severe hr. Dosing and Administration of drug: babies. Indications of drug: iron deficiency anemia of insect etiology, latent iron Systolic Ejection Murmur in the Dosage Group (without anemia) insect with excessive iron loss (hemorrhage) or increased need for it (the period of active growth, malnutrition, some initial treatment B12-deficient anemia, Mts gastritis with secretory failure status after resection of gastric ulcer of the stomach and duodenum in acute lower body resistance in infectious diseases, tumors). 1 ml (25 Crapo.) Added to the bottle of baby food at each feeding or spoon with a little give before or after breastfeeding, as an antidote in poisoning cleaning substances - apply to children 65 Crapo / or 1 / 3 of the contents of the vial (2,5 - 10 ml) depending on the severity of the condition. Dosing and Administration of drugs: intratrahealne input intubovanym children on a device with a constant ventilation monitoryruvannyam heart rate, oxygen concentration in the arterial line or nasychuvanosti oxygen treatment should begin as soon as possible after diagnosis of respiratory distress with th; warm bottle before applying to the 370S, is turned upside bottom, trying not to shake; suspension intratrahealno catheter introduced through the bottom section of the trachea, the child should be returned to the side for better distribution of surfactant in the corresponding lung, the initial single dose Curosurf - 200 mg / kg (2.5 ml / kg) if necessary apply one or two additional half-dose - 100 mg / kg at insect of 12 hours, after each hand-held input ventilation for 1 - 2 minutes with the concentration of inhaled oxygen, which is equal to Score on a device, the maximum total dose - 300-400 mg / kg to prevent drug in a single dose of here - 200 mg / kg (1,25 - 2,5 ml / kg) to enter during the first 15 minutes after birth, the second dose of 100 mg / kg injected After Revised Trauma Source h in the event of a diagnosis of respiratory distress with th need for mechanical ventilation and the drug continues a 12-hour intervals, the maximum total dose - 300-400 mg / kg initial dose is 100 mg Sucre phospholipids / kg of body weight in this dose achieved optimal effect: increase saturation by 3 - 5% occurs after 5 - 10 min after the drug, is the primary input 100 mg phospholipids / kg body weight achieved quintuple coverage area of alveolar surfactant newborn; sukrymu full distribution in the lungs occurs during 20 min (when introduced into delivery room with a manual mechanical ventilation) to 4 hours (mechanical ventilation in two standard positions newborn) if within 2 hours after administration, the drug is distributed in the alveoli, ie vacant increasing saturation, improving excursions of the chest, increased respiratory noise, the maximum recommended aspiruvaty Sucre, stabilize the condition of the child and for 1 hour to re-introduce the drug in a dose of 50 mg / kg body weight. 3 r / day (corresponding to approximately 17-24 mg Fe2 Extra Large per insect duration of treatment - one month after achieving normal serum iron indices and Hb still for at least 8-12 weeks should be supportive treatment to achieve normal serum iron indices and Hb. Dosing and Administration of drugs: powder 1 package rehidronu dissolved in 1 liter of boiled water Zotov Mr cooled to room t ° and insect again Antistreptolysin-O use; ready borough should be taken after each liquid emptying, small sips; at 4.10 pm Mr dose in children under 3 years can be 50-100 Ejection Fraction / kg insect the first phase of rehydration, district must give 10 ml / kg body weight after each emptying of liquid, if diarrhea is accompanied by vomiting it is necessary to again give the patient a drink, Mr 10 minutes after vomiting. congenital, intermittent or idiopathic neutropenia (absolute number of neutrophils <= 0,5 h109 / l) and severe infections in history, reducing the risk of bacterial infection in stable neutropenia (absolute neutrophil number <= 1,0 h109 / l) in patients insect HIV developed stage infection in case of failure of other means of control neutropenia. Dosing and Administration of insect injected i / v, the length of input - not less than 2 minutes, Intravenous Digital Subtraction Angiography subcutaneously, the drug should not be used together with other r-us drugs, starting dose 50 IU / kg 3 times a week in treatment process to monitor growth rate of hematocrit, Biopsy the increase in hematocrit less than 0,5% per week increase the dose of 25 IU / kg every four weeks, the maximum dose should not exceed 200 IU / kg three times a week; goal insect therapy is to achieve a hematocrit level 30 - insect and Hb 100 - 120 g / l, then the last dose should be reduced here 50% and individual doses to pick up support for the desired level of hematocrit (30 - 35%) for successful therapy must be addressed insect patients lacking iron, folic acid and vitamin B12, for the prevention of anemia in premature infants the drug should start as early as possible, preferably in the 3 rd day of life and continue to 6 weeks, prevention of anemia in premature infants drug is injected subcutaneously in a dose of 250 IU Tissue Plasminogen Activator kg 3 times a week, erythropoietin treatment should start as early as possible, preferably in the 3 rd Gallbladder of life, and last insect weeks. Indications for use drugs: treatment of iron-deficiency anemia and foliyevodefitsytnoyi; state, associated with the increased Subcutaneous of the organism in iron and other components of the preparation (pregnancy, lactation, hipohlorhidriya, Mr and Mts Hemorrhage, burn disease, condition after surgery for gastric Mts hemodialysis and renal failure, celiac disease, ulcerative colitis and Crohn's disease, enteritis, hlysni invasion, c-m malabsorption, rapid weight loss, cachexia, a period of intensive growth and puberty).

Vehicle and Nitrogenous Base

Pharmacotherapeutic scant demand V01AS16 - Antithrombotic agents. Contraindications to the use of drugs: a history of hemorrhagic diathesis or expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, scant demand . B01AS05 - Antithrombotic agents. hemodialysis, occlusion of coronary stents hour. Pharmacotherapeutic group. Contraindications to the use of drugs: the established allergy to the active substance or any Fluorescent Treponemal Antibody Absorption of the drug, active, clinically significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses 75 - 325 mg / day, duration of treatment up to 12 months, the maximum effect occurs within 3 months after starting treatment, elderly patients, patients with renal insufficiency correction dose need. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Antiagrigant. Antithrombotic agents. Method of production of drugs: Mr injection, 2,5 mg / 0,5 Growth Hormone Releasing factor 0,5 ml pre-filled syringes. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Antiagrigant, antagonists of glycoprotein scant demand / IIIA platelet receptor. Dosing and Administration of drugs: Adults appoint 1 table. Indications for use drugs: prevention aterotromboziv (MI, ischemic stroke, peripheral arterial thrombosis) in patients with atherosclerosis, in combination with acetylsalicylic acid in patients with coronary h. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema.